Memorial Sloan Kettering Cancer Center
Dr. Autio is a member of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center in New York, with a dual appointment in the Early Drug Development (EDD) Service with a therapeutic research focus on novel immunotherapies. Her research efforts have been aimed at targeting the tumor microenvironment and other combinatorial strategies designed to circumvent immune suppressive resistance mechanisms used by prostate cancer to evade immunotherapy. More recently, she has been evaluating T cell redirectors/bispecific T cell engagers in metastatic castration resistant disease. Alongside these therapeutic efforts, she has advocated for the patient’s voice to be represented in toxicity reporting, incorporating the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), an NIH directed initiative developed to capture symptomatic adverse events as reported directly by patients, into several investigator initiated trials and other PRO efforts. Her research endeavors investigating novel agents as well as those efforts focused on patient reported outcome measures serve to improve the lives of patients at all stages of prostate cancer.
Amgen, (Individual(s) Involved: Self): Grant/Research Support; Astra Zeneca (Individual(s) Involved: Self): Grant/Research Support; CytomX Therapeutics (Individual(s) Involved: Self): Grant/Research Support; Eli Lilly Pharmaceuticals (Individual(s) Involved: Self): Grant/Research Support; Janssen (Individual(s) Involved: Self): Grant/Research Support; Parker Institute for Cancer Immunotherapy (Individual(s) Involved: Self): Grant/Research Support; Pfizer, Inc. (Individual(s) Involved: Self): Grant/Research Support; Trishula (Individual(s) Involved: Self): Grant/Research Support
Thursday, September 29, 2022
1:40 PM – 3:10 PM
Thursday, September 29, 2022
2:05 PM – 2:25 PM
Thursday, September 29, 2022
2:45 PM – 3:10 PM